ZYNLONTA® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL Safety and tolerability data were consistent with the...

Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced that the Company is scheduled to participate in...

The American Solar Energy Society (ASES) proudly announces the recipients of the 2025 ASES Awards and Fellow Inductions, honoring individuals who have demonstrated outstanding leadership,...

Event to Unveil the Next Phase of PartnerOps Framework with a Focus on Scalable Growth Through Ecosystem Collaboration PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- ZINFI Technologies, Inc., a...

– Late-breaking poster abstract highlights physician-reported treatment patterns and characteristics of patients with systemic lupus erythematosus treated with Acthar Gel1 – DUBLIN, May 14,...